Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Other ETFs median (73 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 16 Nov 2022 – 20 Aug 2026, limited by HDFC NIFTY Private Bank ETF. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HDFC NIFTY Private Bank ETF | Nifty Bank |
|---|---|---|
| 16 Nov 2022 | ₹100.00 | ₹100.00 |
| 10 Mar 2023 | ₹95.17 | ₹95.18 |
| 03 Jul 2023 | ₹106.91 | ₹106.17 |
| 25 Oct 2023 | ₹103.43 | ₹100.70 |
| 17 Feb 2024 | ₹107.96 | ₹109.05 |
| 10 Jun 2024 | ₹114.99 | ₹117.03 |
| 03 Oct 2024 | ₹120.47 | ₹121.89 |
| 25 Jan 2025 | ₹110.96 | ₹113.71 |
| 19 May 2025 | ₹129.05 | ₹130.29 |
| 11 Sep 2025 | ₹124.89 | ₹128.53 |
| 03 Jan 2026 | ₹135.58 | ₹141.41 |
| 28 Apr 2026 | ₹123.77 | ₹130.25 |
| 20 Aug 2026 | ₹129.40 | ₹135.17 |
| Metric | HDFC NAV ₹28.02 Very High risk ★☆☆☆☆ | Category median Other ETFs · 73 funds |
|---|---|---|
| +2.37% | +4.04% | |
| +7.13% | +10.87% | |
| — | +9.30% | |
| — | +11.96% | |
| +7.10% | +11.34% | |
| +6.06% | — | |
| +8.74% | +14.16% | |
| — | +14.63% | |
| — | +13.16% | |
| Risk | ||
| 16.04% | 14.74% | |
| 0.04 | 0.30 | |
| 0.06 | 0.42 | |
| -17.30% | -21.01% | |
| Nifty Bank | — | |
| -2.38% | +0.59% | |
| 0.96 | 1.00 | |
| 87.6% | 100.9% | |
| 96.2% | 97.8% | |
| 0.16% | 0.29% | |
| ₹370.14Cr | ₹143.12Cr | |
| — | — | |
| — | — | |
| — | — | |
| ₹100 | — | |
| — | — | |
| Arun Agarwal | — | |
| 16 Nov 2022 | — | |
| 10 | — | |
| 99.7% | — | |
| — | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.